National Institute of Allergy & Infectious Diseases: Investigational COVID-19 Vaccine Well-Tolerated and Generates Immune Response in Older Adults
September 30, 2020
September 30, 2020
WASHINGTON, Sept. 30 -- The U.S. Department of Health and Human Services' National Institute of Allergy and Infectious Diseases issued the following news release on Sept. 29:
A Phase 1 trial of an investigational mRNA vaccine to prevent SARS-CoV-2 infection has shown that the vaccine is well-tolerated and generates a strong immune response in older adults. A report published today in the New England Journal of Medicine describes the findings from the study, which was supported . . .
A Phase 1 trial of an investigational mRNA vaccine to prevent SARS-CoV-2 infection has shown that the vaccine is well-tolerated and generates a strong immune response in older adults. A report published today in the New England Journal of Medicine describes the findings from the study, which was supported . . .